Combining gene therapy and chemotherapy to treat aggressive breast cancer
Combine mitochondrial gene therapy and synthetic lethal chemotherapy to treat triple-negative breast cancer
This study is exploring a new way to treat triple-negative breast cancer by using a combination of gene therapy and special chemotherapy to target the energy centers of cancer cells, with the hope of making treatments work better and stopping the cancer from becoming resistant to drugs.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11094833 on NIH RePORTER |
What this research studies
This research investigates a novel approach to treating triple-negative breast cancer (TNBC) by combining mitochondrial gene therapy with synthetic lethal chemotherapy. The study aims to enhance the effectiveness of existing treatments by targeting the mitochondria of cancer cells, which play a crucial role in cell function and survival. By using advanced techniques to disrupt mitochondrial function, the research seeks to induce cancer cell death and prevent the development of drug resistance. Patients may be involved in clinical trials assessing the safety and efficacy of this combined treatment strategy.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple-negative breast cancer who have not responded well to standard chemotherapy treatments.
Not a fit: Patients with non-triple-negative breast cancer or those who have already exhausted all treatment options may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for patients with triple-negative breast cancer, potentially improving survival rates.
How similar studies have performed: Previous research has shown promising results with similar approaches targeting mitochondrial functions in cancer therapy, indicating potential for success in this novel strategy.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Liu, Xiaoguang Margaret — Ohio State University
- Study coordinator: Liu, Xiaoguang Margaret
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.